Ozado Partners

Ozado Bio is a preclinical-stage biotechnology company focused on developing novel therapeutics for degenerative retinal diseases, including age-related macular degeneration (AMD). The company leverages a deep understanding of mitochondrial biology and oxidative stress to develop treatments that protect retinal cells from damage and death. Founded by Dr. Thomas Chalberg, who previously founded Avalanche Biotechnologies, Ozado Bio aims to address the significant unmet need in geographic atrophy and other forms of vision loss. The company's approach involves identifying small molecules that can stabilize mitochondrial function and reduce the impact of cellular stress in the eye. Ozado Bio operates within the Ozado Partners venture studio, which focuses on building high-impact life science companies. The firm is currently advancing its lead programs through early-stage development to establish a pipeline of disease-modifying ophthalmic drugs.